Navigation Links
'Obscurins' in breast tissue may help physicians predict and detect breast cancer
Date:3/21/2012

Bethesda, MDA new discovery published online in The FASEB Journal (http://www.fasebj.org) may lead to a new tool to help physicians assess breast cancer risk as well as diagnose the disease. In the report, researchers from Johns Hopkins University and the University of Maryland, explain how proteins, called "obscurins," once believed to only be in muscle cells, act as "tumor suppressor genes" in the breast. When their expression is lost, or their genes mutated in epithelial cells of the breast, cancer develops. It promises to tell physicians how breast cancer develops and/or how likely it is.

"Our studies on the role of obscurins in the development of breast cancer lay the framework for a series of in-depth investigations aiming to understand how these proteins act to prevent tumor formation," said Aikaterini Kontrogianni-Konstantopoulos, Ph.D., a researcher involved in the work from the Department of Biochemistry and Molecular Biology at the University of Maryland School of Medicine in Baltimore, MD. "It is our hope that our research will provide important new insights into breast tumor biology and ultimately yield new targets for the development of innovative therapeutic strategies."

To make this discovery, Kontrogianni-Konstantopoulos and colleagues used a highly specific antibody probe to detect obscurins in normal and cancerous breast, skin, and colon cells. They observed that cancer cells expressed significantly lower amounts of obscurins compared to normal cells, leading to the hypothesis that loss of obscurins allowed normal cells to become cancerous. The researchers then compared two breast epithelial cell populations: a "normal" one, which expressed obscurins and served as a control, and an "altered" one, which failed to express obscurins through genetic manipulations. Both cell populations were treated with a chemical called "etoposide," which causes massive DNA damage and induces cell death. Scientists detected and quantified cell death with a number of different methodologies, and found that etoposide caused a significantly high percentage of cell death in normal cells, but only a very low percentage of cell death in the altered, obscurin-deficient cells. This suggests that the loss of obscurins makes breast epithelial cells more resistant to the natural cell death necessary to prevent damaged cells from transforming into a run-away cancer.

"This study is important for a number of reasons. First, it shows that there is a lot more to obscurins than previously thought, making future research into this family of proteins important. Second, it reveals a previously unknown group of tumor suppressors in the breast that prevent normal cells from becoming cancerous. Finally, it opens doors to new tools to help doctors assess a person's risk for cancer and possibly to diagnose it in the earliest of stages," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Scotch Plains, NJ (PRWEB) , ... May 24, 2016 , ... ... professional, high quality, patient-oriented dental care. From the moment a patient arrives at ... and Steven Tuckman will work with each and every patient to create a complete ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... CO (PRWEB) , ... May ... ... official announcement of Essette Dashboard, its highly anticipated, web-based software module. The ... platform. The application’s “secret sauce”? Integration with Izenda’s self-service business intelligence solution ...
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today announced the ... pregnant women to prevent morning sickness and promote overall heath. Engineered with advanced ... and taste of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO ...
(Date:5/23/2016)... ... , ... Edward D. Buckingham, M.D . is excited announce that he ... is put out by the National Consumer Advisory Board to honor excellence in medicine. ... for this award. , The National Consumer Advisory Board (NCAB) is a private organization ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... -- The global  reprocessed medical devices market ... according to a new study by Grand View Research, ... the lack of centralized support for waste disposal in ... for reprocessed medical devices market. Additionally, the long-term cost-efficiency ... the original device is the high impact rendering driver ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology: